PF-07209960

N/A

Report date: 2024/10/08 14:02:17

Base Information

Drug NamePF-07209960
Drug Alias NamePF-07209960
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionInterleukin-15 receptor subunit alpha agonistsProgrammed cell death protein 1 blockers
TargetsProgrammed cell death protein 1Interleukin-15 receptor subunit alpha
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungColorectal NeoplasmsCarcinoma, Transitional Cell +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPfizer Inc
Active IndicationsN/A
Inactive IndicationsCarcinoma, Non-Small-Cell LungColorectal NeoplasmsCarcinoma, Transitional Cell +[6] 

Other Information

ATC CodeN/A
Related LinksN/A